Q-omics provides the consensus-scored HDAC6 profile across patient tissues and cancer cell-line models. HDAC6 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, HDAC6 is differentially expressed in 7, with the highest sampling consensus in KICH. Additionally, HDAC6 protein abundance shows 28,558 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight KIRC, KICH, and LUAD as cancer lineages where HDAC6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HDAC6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HDAC6 survival associations across molecular data types. HDAC6 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (9) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HDAC6 RNA expression–survival associations across cancer types. High HDAC6 expression shows unfavorable associations in COAD and ACC, but favorable associations in KIRC, OV, SCLC and MESO. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for HDAC6 RNA expression.
This table summarizes HDAC6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7, while mass-spec protein shows differences in 11. The strongest signals are observed in KICH for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for HDAC6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HDAC6 shows lower tumor expression in KICH, THCA and KIRP and higher tumor expression in BLCA, STAD and COAD. The KICH box plot shows higher HDAC6 RNA expression in normal versus tumor tissue (log2 FC = −1.227, t-test p < 0.001).
This table shows molecular features associated with HDAC6 in patient tissues and cancer cell lines. In patient samples, HDAC6 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, HDAC6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUSC, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
